Agios Pharmaceuticals Inc (NASDAQ: AGIO) has reported E.P.S. of $16.65 for its third fiscal quarter (ending September 30) versus $-1.64 for the same period a year ago — a decline of -1115%. For the latest four quarters through September 30, E.P.S. were $11.86 compared to $-3.94 a year ago — a decline of -401%.
Recent Price Action
Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock closed at $44.43 on 10/31/24 after a decline of -4.0%. Moreover, this decline was accompanied by above average trading volume at 121% of normal. The stock is unchanged during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, AGIO is expected to be a modest Value Builder.
Agios Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Agios Pharmaceuticals has a very low Appreciation Score of 14 but a good Power Rating of 85, with the Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment